Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia.
OBJECTIVE
This study examined whether subcortical volumes of the basal ganglia and thalamus in schizophrenic patients are related to neuroleptic exposure and symptom severity.


METHODS
Basal ganglia substructures and thalamic volumes were measured with magnetic resonance imaging in 96 patients with schizophrenia (50 men and 46 women) and 128 healthy comparison subjects (60 men and 68 women). Twenty-one of the patients were neuroleptic-naive; of the 75 previously treated patients, 48 had received typical neuroleptics only, and 27 had received typical and atypical neuroleptics. The relation of volume measures to treatment status, exposure to neuroleptics, and symptoms was examined.


RESULTS
The neuroleptic-naive patients did not differ from the healthy comparison subjects in subcortical volumes except for lower thalamic volume. In the neuroleptic-naive group, volumes did not correlate with severity of negative symptoms, but higher volumes in both the thalamus and the putamen were associated with more severe positive symptoms. The previously treated group showed higher volumes in the putamen and globus pallidus than the healthy comparison subjects and the neuroleptic-naive patients. In the treated group, a higher dose of a typical neuroleptic was associated with higher caudate, putamen, and thalamus volumes, whereas a higher dose of an atypical neuroleptic was associated only with higher thalamic volume. Higher subcortical volumes were mildly associated with greater severity of both negative and positive symptoms.


CONCLUSIONS
Increased subcortical volumes in treated schizophrenic patients seem to be medication-induced hypertrophy. This hypertrophy could reflect structural adaptation to receptor blockade and may moderate the effects of neuroleptic treatment.
Gur
R E
RE
Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, USA.
Maany
V
V
Mozley
P D
PD
Swanson
C
C
Bilker
W
W
Gur
R C
RC
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001479:Basal Ganglia / Q000033:anatomy & histology* / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D005917:Globus Pallidus / Q000033:anatomy & histology / Q000187:drug effects; D006801:Humans; D006984:Hypertrophy / Q000139:chemically induced; D008279:Magnetic Resonance Imaging; D008297:Male; D011569:Psychiatric Status Rating Scales; D011699:Putamen / Q000033:anatomy & histology / Q000187:drug effects; D012559:Schizophrenia / Q000175:diagnosis* / Q000188:drug therapy*; D012720:Severity of Illness Index; D013788:Thalamus / Q000033:anatomy & histology* / Q000187:drug effects
D014150:Antipsychotic Agents